Humoral immune response and protection from viral infection in mice vaccinated with inactivated MHV-68: Effects of type I interferon

Journal of Interferon and Cytokine Research

Volumn 22, Issue 11, 2002, Pages 1081-1088

  Aricò, Eleonora ^a   Robertson, Kevin ^b   Allen, Deborah ^b   Ferrantini, Maria ^a   Belardelli, Filippo ^a   Nash, Anthony A ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; HERPES VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; HEAT; HERPES VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TREATMENT OUTCOME; VACCINATION; VIRUS INACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL LINE; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON TYPE I; MICE; MICE, INBRED C57BL; VACCINES, INACTIVATED; VIRAL VACCINES;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; MURINAE; MURINE HEPATITIS VIRUS;

EID: 12244255068     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900260442502     Document Type: Article

References (35)

1. Khanna, R., Moss, D.J., and Burrows, S.R. (1999). Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytataxic T-cell-mediated immune regulation. Immunal. Rev. 170, 49-64.
2. Blaskovic, D., Stancekova, M., Svobodova, J., and Mistrikova, J. (1980). Isolation of live strains of herpesviruses from two species of free living small rodents. Acta Virol. 24, 468.
3. Nash, A.A., and Sunil-Chandra, N.P. (1994). Interactions of the murine gammaherpesvirus with the immune system. Curr. Opin. Immunol. 6, 560-563.
4. Sunil-Chandra, N.P., Efstathiou, S., Arno, J., and Nash, A.A. (1992). Virological and pathological features of mice infected with murine gammaherpesvirus 68. J. Gen. Virol. 73, 2347-2356.
5. Virgin, H.W., Latreille, P., Wamsley, P., Hallsworth, K., Weck, K.E., Dal Canto, A.J., and Speck, S.H. (1997). Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71, 5894-5904.
6. Efstathiou, S., Ho, Y.M., Hall, S., Styles, C.J., Scott, S.D., and Gompels, U.A. (1990). Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri. J. Gen. Virol. 71, 1365-1372.
7. Efstathiou, S., Ho, Y.M., and Minson, A.C. (1990). Cloning and molecular characterization of the murine herpesvirus 68 genome. J. Gen. Virol. 71, 1355-1364.
8. Stewart, J.P., Usherwood, E.J., Ross, A., Dyson, H., and Nash, A.A. (1998). Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J. Exp. Med. 187, 19411951.
9. Weck, K.E., Kim, S.S., Virgin, H.W., IV, and Speck, S.H. (1999). B cells regulate murine gammaherpesvirus 68 latency. J. Virol. 73, 4651-4661.
10. Tripp, R.A., Hamilton-Easton, A.M., Cardin, R.D., Nguyen, P., Behm, F.G., Woodland, D.L., Doherty, P.C., and Blackman, M.A. (1997). Pathagenesis of an infectious mononucleosis-like disease induced by a murine gamma-her-pesvirus: Role for a viral superantigen? J. Exp. Med. 185, 16411650.
11. + T cells. J. Exp. Med. 184, 863-871.
12. Stewart, J.P., Micali, N., Usherwood, E.J., Bonina, L., and Nash, A.A. (1999). Murine gammaherpes 68 glycoprotein 150 protects against virus-induced mononucleosis: A model system for gammaherpesvirus vaccination. Vaccine 17, 152-157.
13. Liu, L., Usherwood, E.J., Blackman, M.A., and Woodland, D.L. (1999). T cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. J. Virol. 73, 9849-9857.
14. Usherwood, E.J., Ward, K.A., Blackman, M.A., Stewart, J.P., and Woodland, D.L. (2001). Latent antigen vaccination in a model gammaherpesvirus infection. J. Virol. 75, 8283-8288.
15. Berzofsky, J.A., Ahlers, J.D., and Belyakov, I.M. (2001). Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 3, 209-219.
16. Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., and Tough, D.F. (2001). Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470.
17. Santini, S.M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Di Pucchio, T., and Belardelli, F. (2000). Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191, 1777-1788.
18. Proietti, E., Bracci, L., Puzelli, S., Di Pucchio, T., Sestili, P., De Vincenzi, E., Venditti, M., Capone, I., Seif, I., De Maeyer, E., Tough, D., Donatelli, I., and Belardelli, F. (2002). Type I IFN as a natural adjuvant for a protective immune response: Lessons from the influenza vaccine model. J. Immunol. 169, 375-383.
19. Belardelli, F. (1995). Role of interferons and other cytokines in the regulation of the immune response. APMIS 103, 161-179.
20. Bogdan, C. (2000). The function of type I interferons in antimicrobial immunity. Curr. Opin. Immunol. 12, 419-424.
21. Belardelli, F., and Gresser, I. (1996). The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol. Today 17, 369-372.
22. Tovey, M.G., Begon-Lours, J., and Gresser, I. (1974). A method for the large-scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809-815.
23. Murphy, B.R., and Chanock, R.M. (1996). Immunization against virus disease. In: Fields Virology, 3rd Ed. B.N. Fields, D.M. Knipe, and P.M. Howly (eds.) Philadelphia: Lippincott-Raven Publishers.
24. Braun, W., and Levy, H.B. (1972). Interferon preparations as modifiers of the immune response. Proc. Soc. Exp. Biol. Med. 141, 769-773.
25. Brodeur, B.R., and Merigan, T.C. (1974). Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J. Immunol. 113, 1319-1325.
26. Brodeur, B.R., and Merigan, T.C. (1975). Mechanism of the suppressive effect of interferon on antibody synthesis in vivo. J. Immunol. 114, 1323-1328.
27. Chester, T.J., Paucker, K., and Merigan, T.C. (1973). Suppression of mouse antibody producing spleen cells by various interferon preparations. Nature 246, 92-94.
28. Strannegard, O., Larsson, I., Lundgren, E., Miornor, H., and Persson, H. (1978). Modulation of immune responses in newborn and adult mice by interferon. Infect. Immun. 20, 334-339.
29. Vignaux, F., Gresser, I., and Fridman, W.H. (1980). Effect of virus-induced interferon on the antibody response of suckling and adult mice. Eur. J. Immunol. 10, 767-772.
30. β treatment in mice. J. Exp. Med. 173, 1193-1203.
31. Finkelman, F.D., Svetic, A., Gresser, I., Snapper, C., Holmes, J., Trotta, P.P., Katona, I.M., and Gause, W.C. (1991). Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174, 1179-1188.
32. Klaus, G., Pepys, M.B., Kitajima, K., and Askonas, B.A. (1979). Activation of mouse complement by different classes of mouse antibody. Immunology 38, 687-695.
33. Coutelier, J.P., Van Der Logt, J.T., and Heessen, F.W. (1991). IgG subclass distribution of primary and secondary immune responses concomitant with viral infection. J. Immunol. 147, 1383-1386.
34. Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F.M., Gessner, J.E., Schiller, C., Schmidt, R.E., Honjo, T., Verbeek, J.S., and Izui, S. (2000). Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in viva with the low-affinity Fc gamma receptor HI. J. Exp. Med. 191, 1293-1302.
35. Dutia, B.M., Allen, D.J., Dyson, H., and Nash, A.A. (1999). Type I interferons and IRF-I play a critical role in the control of gammaherpesvirus infection. Virology 261, 173-179.